Biosynth

Sourcing disease state serum and plasma is complex, time-consuming, and often unavailable—creating challenges for diagnostic assay development. That’s why Biosynth offers human hybrid IgM monoclonal antibodies as a reliable alternative to IgM plasma. These novel alternatives offer: Lot-to-lot consistency  High specificity  ISO13485-certified production  A reliable source Inquire about Biosynth’s human hybrid IgM monoclonal antibodies today https://lnkd.in/emXx4MQH   Learn more about the role of disease state matrices, the limitations of IgM plasma, and Biosynth’s hybrid IgM antibody solution in our blog https://lnkd.in/e-uMzWHF #diagnostics #assaydevelopment #plasma #serum #diseasestateplasma #antibodies #controls

Diagnostic industries rely on a continuous source of antibody-rich plasma for the manufacture of positive controls and calibrators, as well as for purification purposes. Biosynth provides bulk disease-state plasma and serum to in vitro diagnostic manufacturers worldwide. We specialize in infectious diseases, autoimmune and allergy disorders, serum proteins, and myeloma plasma. Whether you are developing a new diagnostic assay or on the cusp of discovering a novel biomarker, Biosynth’s biospecimens, serum, plasma, and blood can help https://lnkd.in/esy-e4JE #diagnostics #IVD #plasma #serum #biospecimens #controls #calibrators #assaydevelopment #biomarkers #diseasestate

Enzymes are powerful biomarkers and diagnostic tools driving the rapid rise in sensitive diagnostic assays. In the first of our two-part blog series, we will explore how enzymes are key biomarkers for illnesses such as cardiac disorders, cancer and bone, liver, and neurodegenerative diseases. Read the full blog here https://lnkd.in/e5DgSBZB At Biosynth, our extensive enzyme portfolio is designed to support your research and diagnostic development needs. Whether you're looking for high-specificity enzymes for analyte detection or signal amplification, we’ve got you covered. Need a custom enzyme? Our enzyme services include:  Enzyme identification  Process development  ISO 9001:2015-compliant manufacturing  Scale-up from milligrams to multi-kilograms Find out more on our website https://lnkd.in/eqcmJH52 #Diagnostics #Enzymes #Biomarkers #LifeSciences #ELISA #Biosensors #Biotech

A new disease threat watch list for pathogens this morning published in the UK (https://lnkd.in/eaQjDD8r). Biosynth has an extensive range of reagents for diagnostics (including antigens, antibodies and plasma) as well as development services and material supply for those developing vaccines and treatment within life sciences. Developing a full disease library to address the needs of our customers means we are constantly updating both diseases and strains as they are reported. Here is the full list of diseases on the UK watch list - Adenovirus, Lassa fever, Norovirus, Mers, Ebola (and similar viruses, such as Marburg), Flaviviridae (which includes dengue, Zika and hepatitis C), Hantavirus, Crimean-Congo haemorrhagic fever, Flu (non-seasonal, including avian), Nipah virus, Oropouche, Rift Valley fever, acute flaccid myelitis, Human metapneumovirus (HMPV), Mpox, Chikungunya, Anthrax, Q fever, Enterobacteriaceae (such as E. coli and Yersinia pestis), Tularaemia, Moraxellaceae (which cause lung, urine and bloodstream infections), Gonorrhoea, Staplylococcus, Group A and B Strep. #diagnostics #pathogens #biosynthdiagnostics

Day one of CACLP 2025! The Biosynth team is looking forward to connecting with you to discuss how we can support your diagnostic projects. Whether you're working on custom solutions or need raw materials for your diagnostic assays, we are here to help. We offer a wide a range of biological reagents, research kits, and research area-specific products including those for emerging infectious diseases, veterinary science, cancer, neurology, and more. Visit our diagnostic reagents for IVD webpage to discover our full offering: https://lnkd.in/d4f2Zx4P 📍 Find us at Hall 4, Booth E0305 Stop by to meet Philip Noone. CDir, Dongjia(Davy) Lu, and Pragya Maheshwari, and discuss how our solutions can enhance your IVD projects. #CACLP2025 #IVD #Diagnostics

Custom peptide expertise for optimizing your CPP. Our expert team can provide unparalleled peptide synthesis and conjugation services, crafting precise molecules for your research. From standard sequences to tailored creations, we modify CPPs to your exact needs. Our seamless conjugation services expertly link your payload to a variety of CPPs, ensuring efficient delivery and optimal results. For a comprehensive guide to CPP selection, visit our blog. https://lnkd.in/e2bfpYAa Explore limitless possibilities with our custom peptide synthesis, diverse modifications, and flexible functionalization options, and contact us today. https://lnkd.in/dBc_HQFV #CustomSynthesis #Peptide #PeptideSynthesis #Biosynth #CPP #CellPenetratingPeptide

Synthetic enzyme substrates are revolutionizing the pharmaceutical industry, offering an alternative to traditional methods. Producing a measurable signal in the presence of specific bacteria, these have advantages over other methods including: • Specificity - target particular enzymes  • Speed - signals are detected quickly, usually without additional tests  • Economic viability - more cost-effective Read our most recent blog to delve into the different types of enzyme substrates and their implications for microbiology and clinical diagnostic applications. https://lnkd.in/e7ji4VC7 Biosynth have developed a range of innovative enzyme substrates over the years for applications in diagnostics, culture media, food and environmental testing.  To find out more about our diverse range of substrates, including chromogenic, fluorogenic and bioluminescent substrates, visit us today. https://lnkd.in/etifGfsX #EnzymeSubstrates #Microbiology #Diagnostics #BacterialDetection #Biosynth #Innovation 

Sourcing characterized disease state serum and plasma is complicated, time-consuming and sometimes suitable material is not available at all. This is a challenge in diagnostic assay development, where such materials are necessary to produce positive and negative controls. That is why Biosynth offers our customers an innovative range of human hybrid IgM monoclonal antibodies as an alternative to hard-to-find human disease IgM plasma. These antibodies have guaranteed lot-to-lot consistency, high specificity, are reliably sourced, and are produced under ISO13485. For more on the role of disease state matrixes in diagnostic tests, the challenges of using IgM plasma/serum, and how Biosynth's hybrid IgM antibodies offer a successful solution, read our blog https://lnkd.in/e-uMzWHF #diagnostics #assaydevelopment #plasma #serum #biofluids #diseasestateplasma #antibodies #controls #innovation

Just one week to go! Biosynth is getting ready for CACLP 2025, the leading event for in vitro diagnostics, taking place from March 22-24 at the Hangzhou Grand Convention & Exhibition Center. As a trusted partner in clinical and veterinary diagnostics, Biosynth provides a comprehensive range of high-quality reagents. With a deep understanding of IVD manufacturing challenges, we offer: scalable solutions, from bulk supply to custom formulations, helping our partners develop reliable and high-performing diagnostic assays. Visit us at Hall 4, Booth E0305 and meet with our team Philip Noone. CDir, Dongjia(Davy) Lu, and Pragya Maheshwari. Let’s discuss how we can help you achieve faster and more reliable diagnostic results. See you in Hangzhou! #CACLP2025 #DiagnosticReagents #IVD #Diagnostics

Complex drug discovery challenges demand innovative solutions. This year's review in RSC Chemical Biology explores the exciting potential of macrocyclic peptides in peptide drug development. https://lnkd.in/eZiDFxjF As Biosynth launches our cutting-edge tricyclic peptide technology, we asked Sangram Kale, our Head of Peptide Discovery, to discuss the implications and future directions of this field. His timely insights offer a perspective on the future of peptide drug development.  #DrugDiscovery #Peptides #ChemicalBiology #Biotechnology #PeptideDrugs #Macrocycles #Research #Innovation